pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,656 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1891Endpoints1465Fierce Biotech779BioSpace767BioPharma Dive555raps254onclive165fda recalls
therapy area
allOncology13094Rare Disease3387Immunology3069Cardiology2866Hematology2335Pulmonology2299Vaccines
  • Global social media bans for teens spark call for rigorous impact research
    Australia became the first country in December 2025 to prohibit social media use for anyone under 16, and Indonesia quickly followed with a similar restriction. The European Union has taken a sligh…
    STAT · 1mo agoNeutral↗ source
  • Grail’s Galleri blood test sees 33% stock jump as FDA hints at favorable advisory panel outlook
    Shares of Grail rose sharply on Monday after the FDA released documents ahead of an advisory committee meeting, suggesting a positive view of the company’s multi‑cancer blood test, Galleri. The up…
    STAT · 2mo agoRegulatoryPositive↗ source
← prev
page 45 of 147
next →
125
fda medwatch117
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • FDA approves Lilly's new combination therapy for advanced breast cancer
    The U.S. Food and Drug Administration has granted approval for a new combination drug regimen developed by Eli Lilly for patients with an advanced form of breast cancer. The therapy pairs two agen…
    STAT · 2mo agoApprovalPositive↗ source
  • Novo presents low-dose CagriSema data showing competitiveness ahead of approval decision
    Novo used its capital markets day in London to unveil new low-dose data for its experimental metabolic therapy CagriSema. The data indicated that CagriSema performed comparably to Eli Lilly's Moun…
    Endpoints · 2mo agoPositive readoutPositive↗ source
  • Novo Nordisk vows to launch five multi-blockbuster drugs by 2030 as it shifts toward consumer-style products
    Novo Nordisk used its London capital markets day to reassure investors that the company will broaden its pipeline and market new medicines more like consumer products than traditional drugs. The C…
    STAT · 2mo agoNeutral↗ source
  • FDA issues rule to allow non-animal testing methods for drug safety
    FDA issued a direct final rule that updates its regulations to clarify that non-animal methods may be used for safety testing of drugs and biological products before they are tested in humans. The…
    fda press · 2mo agoRegulatoryPositive↗ source
  • New KRAS-targeting drug daraxonrasib approved for pancreatic cancer as experts call for $100 billion NIH budget
    The FDA has approved daraxonrasib, a therapy from Revolution Medicines that targets the KRAS mutation in pancreatic cancer. The drug is intended for patients who have already received treatment and…
    STAT · 2mo agoApprovalPositive↗ source
  • Beacon Therapeutics reports successful gene-therapy trial for rare X-linked retinitis pigmentosa
    Beacon Therapeutics announced that its gene-therapy candidate for X-linked retinitis pigmentosa (XLRP) achieved its primary endpoint in a pivotal trial. The result marks a breakthrough for the rar…
    Endpoints · 2mo agoPositive readoutPositive↗ source
  • Congress pushes back on White House plan to place political appointees on NIH grant reviews
    Members of Congress have voiced strong opposition after a leak revealed a White House proposal to create a commission of political appointees that would review every NIH grant. The idea reportedly…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Pentagon defends labeling WuXi AppTec as Chinese military firm, warning of contract limits
    The U.S. Department of Defense is standing by its recent decision to place WuXi AppTec on a list of companies tied to the Chinese military. The designation could bar the contract manufacturing fir…
    Endpoints · 2mo agoRegulatoryNegative↗ source
  • FDA provides minimal comment on Grail cancer test before advisory committee meeting
    The FDA typically releases briefing documents that give a clear stance on a drug or diagnostic's safety and efficacy before its advisory committee convenes. In the upcoming meeting concerning Grai…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • Pfizer and Eli Lilly sign 'most favored nation' pricing deals to share foreign price hikes with US government
    Pfizer and Eli Lilly have entered into “most favored nation” agreements with the Trump administration, according to a recent report. The deals require the two companies to remit a portion of the a…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • FDA approves IntraBio's Aqneursa for rare ataxia-telangiectasia disorder
    FDA has granted approval for Aqneursa, a therapy developed by privately held biotech IntraBio, to treat ataxia-telangiectasia, a rare genetic disorder. The decision expands treatment options for pa…
    Endpoints · 2mo agoApprovalPositive↗ source
  • Telix to acquire German radioisotope maker ITM in deal valued up to $2.35 billion
    Telix Pharmaceuticals announced it will purchase ITM Isotope Technologies Munich SE, a German producer of medical radioisotopes, for an upfront payment of $1.65 billion. The transaction could rise…
    Endpoints · 2mo agoDealNeutral↗ source
  • ADARx aims for $318 million IPO as TRexBio and Retension also file
    ADARx Pharmaceuticals, a siRNA biotech currently in Phase 3 trials, announced plans to raise roughly $318 million through an initial public offering. The company is joining other biotech firms suc…
    Endpoints · 2mo agoDealNeutral↗ source
  • Alkermes' orexin agonist ALKS 7290 shows promise in early-stage ADHD trial
    Alkermes reported results from a Phase 1 study of its orexin agonist ALKS 7290, a drug class previously explored for rare sleep disorders. The trial enrolled adults with moderate to severe ADHD, a…
    STAT · 2mo agoPositive readoutPositive↗ source
  • Novo Nordisk outlines new obesity and consumer-focused strategy, targets five multi-blockbusters by 2030
    Novo Nordisk used its capital markets day to reassure investors by unveiling a plan to broaden its pipeline beyond diabetes and obesity. The company said it will aim to launch at least five multi-b…
    STAT · 2mo agoNeutral↗ source
  • STAT launches first trust-in-science reporter to explore declining public confidence in health research
    Alex Hogan, senior multimedia producer at STAT, hosts the weekly video series STATus Report and recently aired an episode titled “Why is trust in science important?”. The episode notes that public…
    STAT · 2mo agoNeutral↗ source
  • Novo outlines diversification strategy with new pipeline assets and bolt-on deals
    Novo Pharmaceuticals' chief executive Maziar Mike Doustdar used the company's recent capital-markets day in London to lay out a diversification plan. He said the rebranded firm will focus on expand…
    Endpoints · 2mo agoDealPositive↗ source
  • Cue Biopharma's chronic hives drug clears Phase 2 trial, first immunology data after cancer pivot
    Cue Biopharma announced that its candidate for chronic spontaneous urticaria successfully completed a Phase 2 trial in China. The trial marks the company's first clinical data since it shifted its…
    Endpoints · 2mo agoPositive readoutPositive↗ source
  • Addiction clinics see rising cases of kratom and 7-OH withdrawal
    Addiction clinics are seeing a surge in patients dependent on potent kratom and 7-OH products.
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Iambic Therapeutics launches next-gen Enchant AI model and inks R&D partnership with AbbVie
    Iambic Therapeutics, a San Diego‑based biotech founded in 2019, announced the release of the next generation of its Enchant artificial‑intelligence model. The updated model is intended to enhance…
    Endpoints · 2mo agoDealPositive↗ source
  • Experts urge ClinicalTrials.gov to add pregnancy and lactation checkbox to aid trial enrollment
    Patients who are pregnant or nursing often struggle to locate clinical trials that accept them, and clinicians face the same obstacle when advising participants. ClinicalTrials.gov lists more than…
    STAT · 2mo agoPositive↗ source
  • Trump calls for new vaccine while echoing vaccine misinformation
    A recent STAT newsletter reported that President Donald Trump announced he will demand a new vaccine, echoing long-standing vaccine misinformation. The claim was made a day after health secretary R…
    STAT · 2mo agoNegative↗ source
  • STAT launches trust-in-science reporter to explore public skepticism of modern medicine
    STAT has added a new reporter, Nicholas Florko, to cover trust in science and examine why many people doubt modern medicine. Florko, who also deals with personal health issues such as high cholest…
    STAT · 2mo agoNeutral↗ source